Arg/Arg homozygous for the Gly16Arg polymorphism in ADRB2 have a reduced response to short acting β2-agonists but no effect has been associated with long-acting β2-agonists (LABA)

a Centre for Research in Environmental Epidemiology, Barcelona, Spain b Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain c Arizona Respiratory Center, University of Arizona, Tucson, USA d CIBER Epidemiología y Salud Pública (CIBERESP), Spain e National School of Public Health, Athens, Greece f Respiratory Epidemiology and Public Health Group, National Heart and Lung Institute, Imperial College, London g Department of Medicine and Public Health, University of Verona, Verona, Italy h Centre Hospitalier Universitaire de Grenoble; INSERM U 823; Université Joseph Fourier, Grenoble, France i INSERM U823; Université Joseph Fourier; Grenoble, France j Institute of Lung Biology and Disease /Molecular Pneumology, Helmholtz Zentrum München, Munich-Neuherberg, Germany k Department Medicina e Sanità pubblica, Sezione di Epidemiologia e Statistica Medica, Verona, Italy l Genes and Disease Program, Center for Genomic Regulation, Barcelona, Spain m Division of Respiratory Diseases, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy n Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway o Department of Medical Sciences, Uppsala University, Uppsala, Sweden

[1]  E. Bleecker,et al.  Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. , 2010, American journal of respiratory and critical care medicine.

[2]  P. O'Byrne,et al.  Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. , 2010, The Journal of allergy and clinical immunology.

[3]  J. González,et al.  Traffic-Related Air Pollution, Oxidative Stress Genes, and Asthma (ECHRS) , 2009, Environmental health perspectives.

[4]  X. Estivill,et al.  Joint effect of obesity and TNFA variability on asthma: two international cohort studies , 2009, European Respiratory Journal.

[5]  P. Cooper,et al.  Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways. , 2008, The Journal of allergy and clinical immunology.

[6]  R. Leigh,et al.  A Holy Grail of asthma management: toward understanding how long‐acting β2‐adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids , 2008, British journal of pharmacology.

[7]  E. Bleecker,et al.  Clinical consequences of ADRbeta2 polymorphisms. , 2008, Pharmacogenomics.

[8]  A. Gulsvik,et al.  Asthma control in Europe: a real-world evaluation based on an international population-based study. , 2007, The Journal of allergy and clinical immunology.

[9]  C. Page,et al.  β2-Agonists and bronchial hyperresponsiveness , 2006, Clinical reviews in allergy & immunology.

[10]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[11]  Vernon M. Chinchilli,et al.  β-Adrenergic Receptor Polymorphisms and Response to Salmeterol , 2006 .

[12]  I. Hall,et al.  The effect of β2‐adrenoceptor haplotypes on bronchial hyper‐responsiveness in patients with asthma , 2006, Allergy.

[13]  F. Martinez.  Safety of long-acting beta-agonists--an urgent need to clear the air. , 2005, The New England journal of medicine.

[14]  D. Clayton,et al.  Population structure, differential bias and genomic control in a large-scale, case-control association study , 2005, Nature Genetics.

[15]  J. Ioannidis,et al.  Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. , 2005, The Journal of allergy and clinical immunology.

[16]  E. Israel,et al.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.

[17]  B. Kobilka,et al.  Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox , 2003 .

[18]  J. Mak,et al.  Glucocorticoids reverse IL‐1β‐induced impairment of β‐adrenoceptor‐mediated relaxation and up‐regulation of G‐protein‐coupled receptor kinases , 2002 .

[19]  F Neukirch,et al.  The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. , 2001, The European respiratory journal.

[20]  C. Schramm,et al.  Dexamethasone potentiates high-affinity β-agonist binding and Gsα protein expression in airway smooth muscle , 2000 .

[21]  B. Lipworth,et al.  A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol. , 1999, Chest.

[22]  I. Hall,et al.  Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. , 1997, American journal of respiratory and critical care medicine.

[23]  P. Ghahramani,et al.  Protection by dexamethasone of the functional desensitization to β2‐adrenoceptor‐mediated responses in human lung mast cells , 1997, British journal of pharmacology.

[24]  D. Jarvis,et al.  Variation in nebulizer aerosol output and weight output from the Mefar dosimeter: implications for multicentre studies. , 1997, The European respiratory journal.

[25]  D. Cockcroft,et al.  Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. , 1996, Chest.

[26]  E. Mutius.  Gene-environment interactions in asthma , 2009 .

[27]  A. Tattersfield,et al.  beta-Adrenoceptor polymorphisms: focus moves to long-acting beta-agonists. , 2006, American journal of respiratory and critical care medicine.

[28]  J. Drazen,et al.  Polymorphism of the beta(2)-adrenergic receptor gene and desensitization in human airway smooth muscle. , 2000, American journal of respiratory and critical care medicine.